Caren Mason Net Worth

The estimated Net Worth of Caren L Mason is at least $8.61 Millón dollars as of 6 June 2022. Ms. Mason owns over 68,770 units of Staar Surgical Co stock worth over $4,619,699 and over the last 20 years she sold STAA stock worth over $379,147. In addition, she makes $3,616,040 as President, Chief Executive Officer y Director at Staar Surgical Co.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Mason STAA stock SEC Form 4 insiders trading

Caren has made over 10 trades of the Staar Surgical Co stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 68,770 units of STAA stock worth $599,674 on 6 June 2022.

The largest trade she's ever made was exercising 135,000 units of Staar Surgical Co stock on 1 March 2021 worth over $1,047,600. On average, Caren trades about 20,877 units every 89 days since 2004. As of 6 June 2022 she still owns at least 152,415 units of Staar Surgical Co stock.

You can see the complete history of Ms. Mason stock trades at the bottom of the page.

Caren Mason biography

Caren L. Mason serves as President, Chief Executive Officer, Director of the Company. Ms. Mason was elected to STAAR’s Board of Directors at its 2014 Annual Meeting, and she has served as STAAR’s Chief Executive Officer since March 1, 2015. From 2010 to 2012, Ms. Mason served as Chief Executive Officer of Verinata Health, Inc. (f/k/a Artemis Health, Inc.), a provider of non-invasive prenatal genetic sequencing tests for the early identification of fetal chromosomal abnormalities. In February 2013, Verinata was acquired by Illumina. Ms. Mason served as the President, Chief Executive Officer and a Director of Quidel Corporation from 2004 to 2009, a publicly traded company engaged in the development, anufacturing and marketing of rapid diagnostic solutions at the professional point of care in infectious diseases and reproductive health. Prior to joining Quidel, Ms. Mason provided consultative services from 2003 to 2004 for Eastman Kodak Health Imaging as a result of the sale of MiraMedica, Inc., to Eastman Kodak. She served as President and Chief Executive Officer for MiraMedica, Inc., an early phase start-up developing computer aided detection software for breast cancer, from 2002 through 2003. Prior to her tenure with MiraMedica, Inc., Ms. Mason served as Chief Executive Officer of eMed Technologies of Lexington, Massachusetts, a teleradiology and picture archiving and communications systems usiness. Ms. Mason served as General Manager of the Women’s Healthcare business and as a General Manager in various capacities for the Services business of General Electric Healthcare from 1996 to 2000. Ms. Mason’s additional healthcare experience includes her tenure with Bayer AG/AGFA from 1989 to 1996 where she last held the positions of Senior Vice President for Bayer Corporate Health Care and Senior Vice President for the AGFA Technical Imaging Business Group. Ms. Mason received her B.A. from Indiana University.

What is the salary of Caren Mason?

As the President, Chief Executive Officer y Director of Staar Surgical Co, the total compensation of Caren Mason at Staar Surgical Co is $3,616,040. There are no executives at Staar Surgical Co getting paid more.

How old is Caren Mason?

Caren Mason is 66, she's been the President, Chief Executive Officer y Director of Staar Surgical Co since 2015. There are 2 older and 19 younger executives at Staar Surgical Co. The oldest executive at Staar Surgical Co. is John Moore, 76, who is the Independent Director.

What's Caren Mason's mailing address?

Caren's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.

Insiders trading at Staar Surgical Co

Over the last 21 years, insiders at Staar Surgical Co have traded over $305,974,767 worth of Staar Surgical Co stock and bought 10,576,326 units worth $122,359,752 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Partners, L.P.Bradsher Neal... y Gilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of $1,643,742. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth $49,957.

What does Staar Surgical Co do?

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad

Complete history of Ms. Mason stock trades at QuidelOrtho y Staar Surgical Co

Staar Surgical Co executives and stock owners

Staar Surgical Co executives and other stock owners filed with the SEC include:

• Caren Mason,
  President, Chief Executive Officer, Director
• Scott Barnes,
  Chief Medical Officer
• Keith Holliday,
  Chief Technology Officer
• Caren L. Mason,
  CEO, Pres & Director
• Hans-Martin Blickensdoerfer,
  Senior Vice President - Commercial Operations, Direct Markets Europe and China
• Samuel Gesten,
  Chief Legal Officer, Corporate Secretary
• Dr. Scott D. Barnes M.D.,
  Chief Medical Officer
• James Francese,
  Senior Vice President - Commercial Operations, North America and APAC
• Hans-Martin Blickensdoerfer,
  Sr. VP of Commercial Operations and Director of Markets - Europe & China
• Dr. Keith Holliday,
  Chief Technology Officer
• Patrick F. Williams,
  Chief Financial Officer
• Louis Silverman,
  Independent Chairman of the Board
• Stephen Farrell,
  Independent Director
• John Moore,
  Independent Director
• Patrick Williams,
  Chief Financial Officer
• Gilbert Kliman,
  Director
• Thomas Frinzi,
  Director
• Brian Moore,
  IR Contact Officer
• Jon Hayashida,
  Vice President - Global Clinical and Medical Affairs
• Graydon Hansen,
  Chief Manufacturing Officer and Senior Vice President, Global Operations
• Philippe Subrin,
  VP of Collamer Lens Manufacturing & GM of Nidau Operations
• Joanne Egamino Ph.D.,
  Global Head of Clinical Operations
• James Francese,
  Sr. VP of Commercial Operations - North America & APAC
• William Goodmen,
  VP of Global HR
• Samuel J. Gesten,
  Chief Legal Officer & Corp. Sec.
• Lou Silverman,
  Director
• Stephen P Brown,
  Vice President & Chief Financi
• Richard A Meier,
  Director
• Partners, L.P.Broadwood Cap...,
  
• Partners, L.P.Bradsher Neal...,
  
• William P Wall,
  Director
• David Bailey,
  President and CEO
• Robert Studholme,
  Senior VP, Operations
• Wei Jiang,
  
• Arthur C Butcher,
  
• Nathaniel Sisitsky,
  General Counsel
• Nicholas T Curtis,
  Sr. VP Sales and Marketing
• Paul Hambrick,
  Vice President, Operations
• Robert Kenneth Lally,
  Vice President, QA/RA
• David L Schlotterbeck,
  Director
• James I Farnworth,
  VP Reg Affairs & Quality
• Gunther Roepstorff,
  President - Domilens GmbH
• John R Gilbert,
  Director
• Thomas R Paul,
  Vice President - R & D
• John Bily,
  Chief Financial Officer
• Volker D Anhaeusser,
  Director
• John S Santos,
  Sr. VP Planning & Corp Dev
• Jack Steven Roush,
  
• Charles P Slacik,
  Director
• Robin Hughes,
  Vice President, Marketing
• Mark B Logan,
  Director
• Barry G Caldwell,
  Director
• Don M Bailey,
  Director
• Kathryn Tunstall,
  Director
• Philippe Subrin,
  VP Switzerland OP
• Charles S Kaufman,
  V.P. , General Counsel
• Donald J Todd,
  President, Asia/Pacific
• Donald L Fagen,
  V.P. Sales for N. America
• David R Morrison,
  Director
• Craig Felberg,
  VP, R&D and Clinical Affairs
• William Walter Goodmen,
  Global VP, Human Resources
• Donald Duffy,
  Director
• Isamu Kamijo,
  President, STAAR Japan Inc.
• K Peony Yu,
  Director
• Aimee S Weisner,
  
• Magda Michna,
  Chief Clinical, Regulatory,
• Warren Foust,
  Chief Operating Officer
• Elizabeth Yeu Lin,
  
• Lilian Yansheng Zhou,